Skip to main content

Table 1 Characteristics of studies included in the network meta-analysis

From: Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis

Study Year Region Drugs Size F-up (wks) Efficacy
Ahmad [13] 2008 India Met vs TZDs Met 850 mg bid 31 24 w FPG, FINS, HOMA-IR, BMI, WHR, TT, AND, mF-G score, Menstrual frequency, Adverse events
Rosi 2 mg bid 30
Mohiyididden [14] 2013 UK Met 500 mg bid 17 12 w FPG, FINS, TC, TG, HDL, LDL, BMI, TT, SHBG, Menstrual frequency, Adverse events
Rosi 4 mg qd 18
Yilmaz [15] 2005 Turkey Met 850 mg bid 25 12 w BMI, WHR, AND, HOMA-IR, TC, TG, LDL, HDL, Menstrual frequency, Adverse events
Rosi 4 mg qd 25
Sangeeta [16] 2012 India Met 500 mg bid 50 24 w FINS, HOMA-IR, TC, HDL, mF-G score, TT, SHBG, Menstrual frequency, Adverse events
Pio 15 mg qd 50
Naka [17] 2011 Greece Met 850 mg bid 15 24 w FPG, FINS, TC, TG, HDL, LDL, mF-G score, TT, SHBG, BMI, WHR, Adverse events
Pio 30 mg qd 14
Jensterl [18] 2008 Slovenia Met 850 mg bid 15 24 w FPG, FINS, HOMA-IR, TC, TG, HDL, LDL, BMI, TT, AND, Menstrual frequency, Adverse events
Rosi 4 mg qd 11
Ortega [19] 2005 Mexico Met 850 mg tid 18 24 w FPG, FINS, HOMA-IR, TC, TG, HDL, LDL, BMI, WHR, mF-G score, AND, Adverse events
Pio 30 mg qd 17
Zeng [20] 2020 China Met vs Met + TZDs Met 500 mg tid 44 12 w FPG, FINS, HOMA-IR, TC, TG, HDL, LDL, BMI, TT, Adverse events
Met + Pio 500 mg + 15 mg bid 44
Wang X [21] 2014 China Met 1000 mg tid 43 24 w FPG, FINS, HOMA-IR, HDL, LDL, BMI, WHR, TT, SHBG, mF-G score, Menstrual frequency, Adverse events
Met + Pio 1000 mg + 5 mg tid 43
Liang [22] 2019 China Met vs TZDs vs Met + TZDs Met 500 mg tid 22 12 w FPG, FINS, HOMA-IR, HDL, LDL, TC, TG, BMI, WHR, TT, Menstrual frequency
Pio 30 mg tid 21
Met + Pio 500 mg + 30 mg tid 23
Sohrevardi [23] 2016 Iran Met 500 mg tid 22 12 w PFG, FINS, HOMA-IR, TC, TG, HDL, LDL, BMI, TT, WHR, Menstrual frequency, Adverse events
Pio 30 mg qd 21
Met + Pio 500 mg + 30 mg tid/qd 23
Jamilian [24] 2017 Iran Met vs MI Met 500 mg tid 30 12 w BMI, SHBG, TT, mF-G score
MI 2 g bid 30
Shokrpour [25] 2019 Iran Met 500 mg tid 27 12 w FPG, FINS, HOMA-IR, BMI, TC, TG, HDL-C, LDL-C
MI 2 g bid 26
Fruzzetti [26] 2016 Italy Met 500 mg tid 22 24 w HOMA-IR, BMI, mF-G score, Menstrual frequency, Adverse events
MI 4 g qd 24
Nehra [27] 2017 India Met 500 mg tid 30 12–24 w FPG, FINS, HOMA-IR, TC, TG, HDL, LDL, TT, BMI, WHR
MI 1 g bid 30
Du [28] 2018 China Met vs MI + DCI Met 500 mg bid 32 24 w FPG, FINS, HOMA-IR, TC, TG, HDL, LDL, AND, TT, SHBG, Menstrual frequency, Adverse events
MI + DCI 550 mg + 13.8 mg bid 32
Pizzo [29] 2014 Italy MI vs DCI MI 4 g qd 25 24 w HOMA-IR, BMI, mF-G score, TT, AND, SHGB, Menstrual frequency
DCI 1 g qd 25
Donne [30] 2019 Italy MI vs MI + DCI MI 4 g qd 10 12–24 w mF-G score, WHR, BMI, Menstrual frequency
MI + DCI 1.1 g + 27.6 mg qd 12
Nordio [31] 2012 Italy MI 2 g bid 24 12–24 w BMI, WHR, FPG, FINS, HOMA-IR, TT, SHBG, AND, Menstrual frequency
MI + DCI 550 mg + 13.8 mg bid 26
Li [32] 2017 China Met vs BBR Met 500 mg bid 29 12 w FPG, FINS, HOMA-IR, TC, TG, HDL, LDL, BMI, TT, Adverse events
BBR 300 mg tid 26
Wang P [33] 2016 China Met vs Met + BBR Met 500 mg tid 42 12 w HOMA-IR, BMI, WHR
Met + BBR 500 mg + 500 mg tid 42
Wang L [34] 2011 China Met 500 mg tid 28 12 w FPG, FINS, HOMA-IR, BMI, TT
Met + BBR 500 mg + 500 mg tid 28
  1. Met Metformin, TZDs thiazolidinediones, Rosi rosiglitazone, Pio pioglitazone, MI myo-inositol, DCI d-chiro-inositol, BBR berberine, TT total testosterone, SHBG sex hormone binding globulin, AND androstenedione, mF-G score modified Ferriman–Gallwey score, BMI body mass index, WHR waist–hip ratio, FPG fasting plasma glucose, FINS fasting insulin, HOMA-IR Homeostatic Model Assessment of Insulin Resistance, TG triglyceride, TC total cholesterol, HDL-C high density lipoprotein cholesterol, LDL-C low density lipoprotein cholesterol